What question did this study set out to answer?

This research aimed to evaluate the effectiveness and safety of telitacicept in treating interstitial lung disease (ILD) linked to specific autoimmune conditions.

April 11, 2026Respiratory Research0 citationsOpen Access

Efficacy and safety of telitacicept in patients with progressive interstitial lung disease associated with antisynthetase syndrome, rheumatoid arthritis, or Sjögren’s syndrome: a prospective observational study

XCXue ChenArmy Medical University MSMingfang SunArmy Medical University YZYing Zhou

Key Points

This research aimed to evaluate the effectiveness and safety of telitacicept in treating interstitial lung disease (ILD) linked to specific autoimmune conditions.
Conducted a prospective observational study on patients with progressive ILD.
Included individuals with antisynthetase syndrome, rheumatoid arthritis, or Sjögren's syndrome.
Evaluated clinical efficacy and safety profile of telitacicept.
Telitacicept showed significant clinical efficacy in improving ILD symptoms.
The treatment exhibited a favorable safety profile among patients.
Findings suggest telitacicept as a promising option for challenging connective tissue diseases.

Abstract

Telitacicept demonstrated significant clinical efficacy and a favorable safety profile in patients with ILD associated with antisynthetase syndrome, rheumatoid arthritis, and Sjögren's syndrome. These findings suggest telitacicept may be a promising therapeutic option for refractory or complex connective tissue disease-associated ILD.

AI에게 질문

Bookmark

View Full Paper